FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Crawford

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Prostate

Co-author Network

Publications

TOP 3
Kyle O Rove; E David Crawford
Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
E David Crawford; Hari K Koul; Craig A Baer; Al Baha Barqawi; M Scott Lucia; Paul D Maroni; Cory A Rove; Kyle O Rove; Priya N Werahera; Francisco G La Rosa
Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens.
Maha Hussain; Subramanian Kanaga Sundaram; Glenn Liu; Carol M Moinpour; Stephen Prescott; David I Quinn; Derek Raghavan; Paul F Schellhammer; Eric Jay Small; Catherine M Tangen; Donna L Berry; E David Crawford; Nancy Ann Dawson; Bryan J Donnelly; Benjamin Ely; Celestia S Higano; Ulka N Vaishampayan; Peter M Venner; Nicholas J Vogelzang; George Wilding; Ian M Thompson
Intermittent versus continuous androgen deprivation in prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Crawford (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kyle O Rove; E David Crawford
Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Current opinion in urology 2013;23(3):208-13.
2013: E David Crawford; Hari K Koul; Craig A Baer; Al Baha Barqawi; M Scott Lucia; Paul D Maroni; Cory A Rove; Kyle O Rove; Priya N Werahera; Francisco G La Rosa
Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens.
The Prostate 2013;73(7):778-87.
2013: Maha Hussain; Subramanian Kanaga Sundaram; Glenn Liu; Carol M Moinpour; Stephen Prescott; David I Quinn; Derek Raghavan; Paul F Schellhammer; Eric Jay Small; Catherine M Tangen; Donna L Berry; E David Crawford; Nancy Ann Dawson; Bryan J Donnelly; Benjamin Ely; Celestia S Higano; Ulka N Vaishampayan; Peter M Venner; Nicholas J Vogelzang; George Wilding; Ian M Thompson
Intermittent versus continuous androgen deprivation in prostate cancer.
The New England journal of medicine 2013;368(14):1314-25.
2013: E David Crawford; Joel Eisner; Bo-Eric Persson
Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607.
The Journal of urology 2013;189(3):1168-9.
2013: Gerald L Andriole; Michael J Barry; Alan Cantor; E David Crawford; Christie McCullum-Hill; Gurdarshan S Sandhu
The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial.
The Journal of urology 2013;189(2):486-92.
2013: Paul F Pinsky; Ian Thompson; Gerald Andriole; Amanda Black; E David Crawford; Robert Grubb; Howard L Parnes
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.
Cancer 2013;119(3):593-601.
2012: E David Crawford; Kyle O Rove
Advanced prostate cancer: therapeutic sequencing, outcomes, and cost implications.
The American journal of managed care 2012;18(5 Spec No.):SP250-3.
2012: E David Crawford; Krystyna P Drewnowska; Sheldon J Freedman; W Lloyd Glover; Thomas K Huisman; Jed C Kaminetsky; Junqi Qian; Kyle O Rove; Edouard J Trabulsi; Mark L Bilowus; David G Bostwick
Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases.
The Journal of urology 2012;188(5):1726-31.
2012: Catherine M Tangen; Nicholas J Vogelzang; George Wilding; E David Crawford; Bryan J Donnelly; Mario A Eisenberger; Celestia S Higano; Maha Hussain; Isaac J Powell; Paul F Schelhammer; Eric J Small; Ian M Thompson
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).
The Journal of urology 2012;188(4):1164-9.
2012: Kyle O Rove; Neal D Shore; Nelson N Stone; Frans M Debruyne; Bob Djavan; Leonard G Gomella; Hari K Koul; M Scott Lucia; Daniel P Petrylak; E David Crawford
Role of testosterone in managing advanced prostate cancer.
Urology 2012;80(4):754-62.
2012: Robert E Schoen; Joel L Weissfeld; Patrick Wright; Lance A Yokochi; Gerald L Andriole; Christine D Berg; Robert S Bresalier; Saundra S Buys; Danielle M Carrick; Timothy Church; E David Crawford; Mona N Fouad; John K Gohagan; Claudine Isaacs; Grant Izmirlian; Christine Cole Johnson; Barnett S Kramer; Adeyinka O Laiyemo; Anthony B Miller; Barbara O'Brien; Paul F Pinsky; Philip C Prorok; Mark P Purdue; Douglas Reding; Thomas L Riley
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.
The New England journal of medicine 2012;366(25):2345-57.
2012: Kyle O Rove; E David Crawford
Editorial comment.
The Journal of urology 2012;187(6):2049; discussion 2050.
2012: Kyle O Rove; E David Crawford
Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.
World journal of urology 2012;30(2):137-42.
2012: Ryan K Berglund; Edith D Canby-Hagino; Peter R Carroll; E David Crawford; Ralph W deVere White; Gabriel P Haas; George P Hemstreet; Bruce A Lowe; Isaac J Powell; Catherine M Tangen; Ian M Thompson; Eric A Klein
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
Urology 2012;79(3):633-7.
2012: Gerald L Andriole; Saundra S Buys; David Chia; Timothy R Church; Jonathan D Clapp; E David Crawford; Mona N Fouad; John K Gohagan; Robert L Grubb; Ann W Hsing; Claudine Isaacs; Grant Izmirlian; Barnett S Kramer; Paul A Kvale; Anthony B Miller; Barbara O'Brien; Paul F Pinsky; Philip C Prorok; Lawrence R Ragard; Joshua M Rathmell; Douglas Reding; Thomas L Riley; Joel L Weissfeld; Lance A Yokochi
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
Journal of the National Cancer Institute 2012;104(2):125-32.
2012: Priya N Werahera; Francisco G La Rosa; Fernando J Kim; M Scott Lucia; Colin O'Donnell; Beth Schulte; Rameshwar S Sidhu; Holly T Sullivan; Kathryn Sullivan; E David Crawford
Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume.
International journal of clinical and experimental pathology 2012;5(9):892-9.
2012: E David Crawford; Thomas W Flaig
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.
Oncology (Williston Park, N.Y.) 2012;26(1):70-7.
2011: Kyle O Rove; E David Crawford
Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival.
Oncology (Williston Park, N.Y.) 2011;25(14):1362-70, 1375-81, 1387.
2011: Martin M Oken; Paul F Pinsky; Philip C Prorok; Lawrence R Ragard; Joshua M Rathmell; Douglas J Reding; Thomas L Riley; Joel L Weissfeld; Patrick Wright; Lance A Yokochi; Gerald L Andriole; Christine D Berg; Saundra S Buys; Neil Caparaso; Timothy R Church; E David Crawford; Mona N Fouad; John K Gohagan; Willam G Hocking; Ping Hu; Claudine Isaacs; Grant Izmirlian; Barnett S Kramer; Paul A Kvale; Anthony B Miller; Barbara O'Brien
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.
JAMA : the journal of the American Medical Association 2011;306(17):1865-73.
2011: E David Crawford; Alexa Hughes; Al Baha Barqawi; Colin I O'Donnell; Michael O'Leary; Claus G Roehrborn; Kathryn F Sullivan; Paul Maroni
Validation of the modified American Urological Association symptom score.
The Journal of urology 2011;186(3):945-8.
2011: E David Crawford; Robert F Donnell; Kathryn Hirst; Steven A Kaplan; John W Kusek; Kevin T McVary; Lance A Mynderse; Claus G Roehrborn; Christopher P Smith; Reginald Bruskewitz
Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial.
The Journal of urology 2011;186(3):965-70.
2011: Al Baha Barqawi; E David Crawford; Alexa Hughes; Michael O'Leary; Claus G Roehrborn; Nelson Stone; Kathryn F Sullivan; Colin I O'Donnell
Methods of developing UWIN, the modified American Urological Association symptom score.
The Journal of urology 2011;186(3):940-4.
2011: E David Crawford; Jens-Kristian Jensen; Kurt Miller; Judd W Moul; Tine Kold Olesen; Fritz Schröder; Neal Shore; Bertrand Tombal; Laurent Boccon-Gibod; Bo-Eric Persson
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
The Journal of urology 2011;186(3):889-97.
2011: Paul Maroni; E David Crawford
Assessment of men before androgen deprivation therapy.
The Journal of urology 2011;186(2):371-2.
2011: Al Baha Barqawi; Saeed Gholizadeh; Hari K Koul; Colin I O'Donnell; Kyle O Rove; E David Crawford
The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer.
The Journal of urology 2011;186(1):80-5.
2011: K O Rove; E David Crawford
Dutasteride: novel milestones in prostate cancer chemoprevention.
Drugs of today (Barcelona, Spain : 1998) 2011;47(2):135-44.
2011: E David Crawford; Robert Grubb; Amanda Black; Gerald L Andriole; Ming-Hui Chen; Grant Izmirlian; Christine D Berg; Anthony V D'Amico
Comorbidity and mortality results from a randomized prostate cancer screening trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(4):355-61.
2011: Priya N Werahera; E David Crawford; Kenneth Easterday; Elizabeth Genova; L Michael Glode; Francisco G La Rosa; M Scott Lucia; Rameshwar S Sidhu; Holly T Sullivan; Tammy E Hedlund
Proliferative tumor doubling times of prostatic carcinoma.
Prostate cancer 2011;2011():301850.
2011: E David Crawford; Jason M Phillips
Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.
Cancer management and research 2011;3():201-9.
2010: E David Crawford; Kyle O Rove
Incomplete testosterone suppression in prostate cancer.
The New England journal of medicine 2010;363(20):1976.
2010: Thomas W Flaig; Michael Glodé; Daniel Gustafson; Adrie van Bokhoven; Yuzhen Tao; Shandra Wilson; Lih-Jen Su; Yuan Li; Gail Harrison; Rajesh Agarwal; E David Crawford; M Scott Lucia; Michael Pollak
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.
The Prostate 2010;70(8):848-55.
2010: E David Crawford; L Black; M Eaddy; E J Kruep
A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer.
Prostate cancer and prostatic diseases 2010;13(2):162-7.
2010: Stella Koutros; Fredrick R Schumacher; Richard B Hayes; Jing Ma; Wen-Yi Huang; Demetrius Albanes; Federico Canzian; STEPHEN CHANOCK; E David Crawford; W Ryan Diver; Heather Spencer Feigelson; Edward Giovanucci; Christopher A Haiman; Brian E Henderson; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Peter Kraft; Loïc Le Marchand; Elio Riboli; Afshan Siddiq; Mier J Stampfer; Daniel O Stram; Gilles Thomas; Ruth C Travis; Michael J Thun; Meredith Yeager; Sonja I Berndt
Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer.
Cancer research 2010;70(6):2389-96.
2010: E David Crawford; Gerald L Andriole; Michael Marberger; Roger S Rittmaster
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.
Urology 2010;75(3):502-9.
2010: Kyle O Rove; Kathryn F Sullivan; E David Crawford
High-intensity focused ultrasound: ready for primetime.
The Urologic clinics of North America 2010;37(1):27-35, Table of Contents.
2009: Kyle O Rove; E David Crawford
Metastatic cancer in solid tumors and clinical outcome: skeletal-related events.
Oncology (Williston Park, N.Y.) 2009;23(14 Suppl 5):21-7.
2009: Yujun Guo; Priya N Werahera; Ramkrishnan Narayanan; Lu Li; Dinesh Kumar; E David Crawford; Jasjit Suri
Image registration accuracy of a 3-dimensional transrectal ultrasound-guided prostate biopsy system.
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 2009;28(11):1561-8.
2009: Lisa Mirabello; Wen-Yi Huang; Jason Y Y Wong; Nilanjan Chatterjee; Douglas Reding; E David Crawford; Immaculata DeVivo; Richard B Hayes; Sharon A Savage
The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer.
Aging cell 2009;8(4):405-13.
2009: E David Crawford; Timothy Connor
Proposed update on substaging metastatic prostate cancer.
Urology 2009;74(1):237.
2009: E David Crawford; Amy H Hou
The role of LHRH antagonists in the treatment of prostate cancer.
Oncology (Williston Park, N.Y.) 2009;23(7):626-30.
2009: E David Crawford
Understanding the epidemiology, natural history, and key pathways involved in prostate cancer.
Urology 2009;73(5 Suppl):S4-10.
2009: Amy H Hou; Kathryn F Sullivan; E David Crawford
Targeted focal therapy for prostate cancer: a review.
Current opinion in urology 2009;19(3):283-9.
2009: Jiyoung Ahn; Demetrius Albanes; Sonja I Berndt; Ulrike Peters; Nilanjan Chatterjee; Neal D Freedman; Christian C Abnet; Wen-Yi Huang; Adam S Kibel; E David Crawford; Stephanie J Weinstein; STEPHEN CHANOCK; Arthur Schatzkin; Richard B Hayes
Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.
Carcinogenesis 2009;30(5):769-76.
2009: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Mortality results from a randomized prostate-cancer screening trial.
The New England journal of medicine 2009;360(13):1310-9.
2009: Robert L Grubb; Amanda Black; Grant Izmirlian; Thomas P Hickey; Paul F Pinsky; Jerome E Mabie; Thomas L Riley; Lawrence R Ragard; Philip C Prorok; Christine D Berg; E David Crawford; Timothy R Church; Gerald L Andriole
Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(3):748-51.
2009: E David Crawford
A review of the use of histrelin acetate in the treatment of prostate cancer.
BJU international 2009;103 Suppl 2():14-22.
2009: Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean A Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith D Canby-Hagino; E David Crawford
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.
The Journal of urology 2009;181(3):956-62.
2008: Robert L Grubb; Paul F Pinsky; Robert T Greenlee; Grant Izmirlian; Anthony B Miller; Thomas P Hickey; Thomas L Riley; Jerome E Mabie; David L Levin; David Chia; Barnett S Kramer; Douglas Reding; Timothy R Church; Lance A Yokochi; Paul A Kvale; Joel L Weissfeld; Donald A Urban; Saundra S Buys; Edward P Gelmann; Lawrence R Ragard; E David Crawford; Philip C Prorok; John K Gohagan; Christine D Berg; Gerald L Andriole
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
BJU international 2008;102(11):1524-30.
2008: Gregory Swanson; Bryan Goldman; Catherine M Tangen; Joseph Chin; Edward Messing; Edith D Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford
The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794.
The Journal of urology 2008;180(6):2453-7; discussion 2458.
2008: Tomasz M Beer; Bryan Goldman; Timothy W Synold; Christopher W Ryan; Lakshmi S Vasist; Peter J Van Veldhuizen; Shaker R Dakhil; Primo Lara; Anibal Drelichman; Maha Hussain; E David Crawford
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Clinical genitourinary cancer 2008;6(2):103-9.
2008: E David Crawford; Per-Anders Abrahamsson
PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
European urology 2008;54(2):262-73.
2008: E David Crawford
Legends in urology.
The Canadian journal of urology 2008;15(3):4044-6.
2008: Feimo Shen; Katsuto Shinohara; Dinesh Kumar; Animesh Khemka; Anne R Simoneau; Priya N Werahera; Lu Li; Yujun Guo; Ramkrishnan Narayanan; Liyang Wei; Al Barqawi; E David Crawford; Christos Davatzikos; Jasjit Suri
Three-dimensional sonography with needle tracking: role in diagnosis and treatment of prostate cancer.
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 2008;27(6):895-905.
2008: Jocelyn M Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R Fears; Nilanjan Chatterjee; Ann W Hsing; E David Crawford; Gerald L Andriole; Rudolf Kaaks; Richard Hayes
Endogenous sex hormones and the risk of prostate cancer: a prospective study.
International journal of cancer. Journal international du cancer 2008;122(10):2345-50.
2008: Natalie J Serkova; Eduard J Gamito; Richard H Jones; Colin O'Donnell; Jaimi L Brown; Spencer Green; Holly Sullivan; Tammy E Hedlund; E David Crawford
The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions.
The Prostate 2008;68(6):620-8.
2008: Zinelabidine Abouelfadel; E David Crawford
Leuprorelin depot injection: patient considerations in the management of prostatic cancer.
Therapeutics and clinical risk management 2008;4(2):513-26.
2008: Paul D Maroni; E David Crawford
The benefits of early androgen blockade.
Best practice & research. Clinical endocrinology & metabolism 2008;22(2):317-29.
2008: Thomas W Flaig; Catherine M Tangen; Maha Hussain; Walter M Stadler; Derek Raghavan; E David Crawford; L Michael Glodé
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1532-6.
2008: Tomasz M Beer; Bryan Goldman; Craig Nichols; Daniel P Petrylak; Manoj Agarwal; Christopher W Ryan; E David Crawford
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Clinical genitourinary cancer 2008;6(1):36-9.
2008: Al B Barqawi; E David Crawford
Emerging role of HIFU as a noninvasive ablative method to treat localized prostate cancer.
Oncology (Williston Park, N.Y.) 2008;22(2):123-9; discussion 129, 133, 137 passim.
2007: Jocelyn Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R Fears; Nilanjan Chatterjee; David Chia; E David Crawford; Rudolf Kaaks; Richard Hayes
IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
International journal of cancer. Journal international du cancer 2007;121(10):2267-73.
2007: Francisco G La Rosa; Thomas W Flaig; Shandra Wilson; E David Crawford; Fernando J Kim
Sarcoidosis in a man with renal carcinoid tumor.
Oncology (Williston Park, N.Y.) 2007;21(13):1593-6.
2007: Al Baha Barqawi; Jeremy B Myers; Colin O'Donnell; E David Crawford
The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
BJU international 2007;100(4):853-7.
2007: M Scott Lucia; Jonathan I Epstein; Phyllis J Goodman; Amy K Darke; Victor E Reuter; Francisco Civantos; Catherine M Tangen; Howard L Parnes; Scott M Lippman; Francisco G La Rosa; Michael W Kattan; E David Crawford; Leslie G Ford; Charles A Coltman; Ian M Thompson
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
Journal of the National Cancer Institute 2007;99(18):1375-83.
2007: Al Baha Barqawi; E David Crawford
The current use and future trends of focal surgical therapy in the management of localized prostate cancer.
Cancer journal (Sudbury, Mass.) 2007;13(5):313-7.
2007: E David Crawford; Al Baha Barqawi; Colin O'Donnell; Abraham Morgentaler
The association of time of day and serum testosterone concentration in a large screening population.
BJU international 2007;100(3):509-13.
2007: Gregory Swanson; William R Carpenter; Ian M Thompson; E David Crawford
Urologists' attitudes regarding cancer clinical research.
Urology 2007;70(1):19-24.
2007: E David Crawford; Ian M Thompson
Controversies regarding screening for prostate cancer.
BJU international 2007;100 Suppl 2():5-7.
2007: Gregory Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith D Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2225-9.
2007: Paul Maroni; E David Crawford
Do tumor characteristics and prognostic factors differ between subsequent rounds of PSA screening for prostate cancer?
Nature clinical practice. Urology 2007;4(5):252-3.
2007: Paul F Pinsky; Gerald L Andriole; E David Crawford; David Chia; Barnett S Kramer; Robert L Grubb; Robert Greenlee; John K Gohagan
Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Cancer 2007;109(8):1689-95.
2007: Thomas Flaig; E David Crawford; Brian Kavanagh; Scott Lucia; Francisco La Rosa; Albaha Barqawi; Frances Crighton; L Michael Glodé
Prostate cancer in a man with multiple previous cancers.
Oncology (Williston Park, N.Y.) 2007;21(5):611-4.
2007: Paul F Pinsky; E David Crawford; Barnett S Kramer; Gerald L Andriole; Edward P Gelmann; Robert L Grubb; Robert Greenlee; John K Gohagan
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
BJU international 2007;99(4):775-9.
2007: Albaha B Barqawi; Li Lu; E David Crawford; Aaron Fenster; Priya N Werahera; Dinesh Kumar; Steve Miller; Jasjit Suri
Three different strategies for real-time prostate capsule volume computation from 3-D end-fire transrectal ultrasound.
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 2007;2007():816-8.
2007: E David Crawford; Albaha Barqawi
Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer.
Oncology (Williston Park, N.Y.) 2007;21(1):27-32; discussion 33-4, 39.
2007: Sonja I Berndt; Nilanjan Chatterjee; Wen-Yi Huang; STEPHEN CHANOCK; Robert Welch; E David Crawford; Richard Hayes
Variant in sex hormone-binding globulin gene and the risk of prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(1):165-8.
2007: Ulrike Peters; Charles B Foster; Nilanjan Chatterjee; Arthur Schatzkin; Douglas Reding; Gerald L Andriole; E David Crawford; Stefan Sturup; STEPHEN CHANOCK; Richard Hayes
Serum selenium and risk of prostate cancer-a nested case-control study.
The American journal of clinical nutrition 2007;85(1):209-17.
2006: Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean A Troyer; Edward Messing; Jeffrey D Forman; Joseph Chin; Gregory Swanson; Edith D Canby-Hagino; E David Crawford
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
JAMA : the journal of the American Medical Association 2006;296(19):2329-35.
2006: Ana Carolina Galtarossa Xavier; Carrie Marshall; Francisco G La Rosa; Luciano J Costa; Harry A Drabkin; E David Crawford
Woman with a papillary pulmonary lesion and a complex renal cyst.
Oncology (Williston Park, N.Y.) 2006;20(11):1437-9, 1443.
2006: E David Crawford; Brian D Kavanagh
The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy.
American journal of clinical oncology 2006;29(5):517-23.
2006: Gregory Swanson; Ian M Thompson; Joseph W Basler; E David Crawford
Metastatic prostate cancer-does treatment of the primary tumor matter?
The Journal of urology 2006;176(4 Pt 1):1292-8.
2006: Maha Hussain; Catherine M Tangen; Celestia S Higano; Paul F Schelhammer; James Faulkner; E David Crawford; George Wilding; Atif Akdas; Eric J Small; Bryan Donnelly; Gary R MacVicar; Derek Raghavan
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(24):3984-90.
2006: Paul F Pinsky; Barnett S Kramer; E David Crawford; Robert L Grubb; Donald A Urban; Gerald L Andriole; David Chia; David L Levin; John K Gohagan
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.
Urology 2006;68(2):352-6.
2006: Thomas D Denberg; L Michael Glodé; John F Steiner; E David Crawford; Richard M Hoffman
Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma.
BJU international 2006;98(2):335-40.
2006: Gregory Swanson; James Faulkner; Stephen R Smalley; Mark J Noble; Ronald L Stephens; Timothy J O'Rourke; Geoffrey R Weiss; Donald P Quick; Ian M Thompson; E David Crawford
Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
The Journal of urology 2006;176(2):548-53; discussion 553.
2006: Tomasz M Beer; Catherine M Tangen; Lisa B Bland; Maha Hussain; Bryan H Goldman; Thomas G Deloughery; E David Crawford
The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
Cancer 2006;107(3):489-96.
2006: Thomas W Flaig; Albaha Barqawi; Gary Miller; Madeleine Kane; Chan Zeng; E David Crawford; L Michael Glodé
A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
Cancer 2006;107(2):266-74.
2006: Donna L Berry; Carol M Moinpour; Caroline S Jiang; Donna Pauler Ankerst; Daniel P Petrylak; Lynne V Vinson; Primo Lara; Sharon Jones; Mary Ellen Taplin; Patrick A Burch; Maha Hussain; E David Crawford
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2828-35.
2006: Tomasz M Beer; Catherine M Tangen; Craig Nichols; Kim Margolin; Robert Dreicer; William T Stephenson; David I Quinn; Derek Raghavan; E David Crawford
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Cancer 2006;106(12):2624-9.
2006: Daniel P Petrylak; Donna Pauler Ankerst; Caroline S Jiang; Catherine M Tangen; Maha Hussain; Primo Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
Journal of the National Cancer Institute 2006;98(8):516-21.
2006: Dominique S Michaud; Sarah E Daugherty; Sonja I Berndt; Elizabeth A Platz; Meredith Yeager; E David Crawford; Ann W Hsing; Wen-Yi Huang; Richard Hayes
Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer.
Cancer research 2006;66(8):4525-30.
2006: Anita L Sabichi; J Jack Lee; Robert J Taylor; Ian M Thompson; Brian J Miles; Catherine M Tangen; Lori M Minasian; Louis L Pisters; John R Caton; Joseph W Basler; Seth P Lerner; David G Menter; James R Marshall; E David Crawford; Scott M Lippman
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2178-84.
2006: Al Baha Barqawi; E David Crawford
Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove.
The Journal of urology 2006;175(4):1572-3; author reply 1573-4.
2006: Abraham Morgentaler; Ernani Luis Rhoden; Al Baha Barqawi; E David Crawford
Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove.
The Journal of urology 2006;175(4):1572; author reply 1573-4.
2006: E David Crawford; Shandra S Wilson; John D McConnell; Kevin Slawin; Michael C Lieber; Joseph A Smith; Alan G Meehan; Oliver M Bautista; William R Noble; John W Kusek; Leroy M Nyberg; Claus G Roehrborn
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
The Journal of urology 2006;175(4):1422-6; discussion 1426-7.
2006: E David Crawford; Paul F Pinsky; David Chia; Barnett S Kramer; Richard M Fagerstrom; Gerald L Andriole; Douglas Reding; Edward P Gelmann; David L Levin; John K Gohagan
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
The Journal of urology 2006;175(4):1286-90; discussion 1290.
2006: Paul D Maroni; E David Crawford
Screening for prostate cancer in 2006: PSA in the 21st century.
North Carolina medical journal 2006;67(2):136-9.
2006: Bulent Akduman; E David Crawford
Comparison of biochemical progression rates after radical prostatectomy and radiotherapy for localized prostate cancer.
Nature clinical practice. Urology 2006;3(2):78-9.
2006: E David Crawford; Oliver Sartor; Franklin Chu; Ramon Perez; Gary Karlin; J Steve Garrett
A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
The Journal of urology 2006;175(2):533-6.
2006: Shandra S Wilson; E David Crawford
Controversies of androgen ablation therapy for metastatic prostate cancer.
Current pharmaceutical design 2006;12(7):799-805.
2006: Victoria A Kirsh; Susan T Mayne; Ulrike Peters; Nilanjan Chatterjee; Michael F Leitzmann; L Beth Dixon; Donald A Urban; E David Crawford; Richard Hayes
A prospective study of lycopene and tomato product intake and risk of prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(1):92-8.
2006: Joseph M Unger; Charles A Coltman; John J Crowley; Laura F Hutchins; Silvana Martino; Robert B Livingston; John S Macdonald; Charles D Blanke; David R Gandara; E David Crawford; Kathy S Albain
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):141-4.
2005: Maha Hussain; Catherine M Tangen; Primo Lara; Ulka Nitin Vaishampayan; Daniel P Petrylak; A Dimitrios Colevas; Wael A Sakr; E David Crawford
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(34):8724-9.
2005: Ashutosh Tewari; Wolfgang Horninger; Alexandre Pelzer; Raymond Demers; E David Crawford; Eduard J Gamito; George Divine; Christine Cole Johnson; George Bartsch; Mani Menon
Factors contributing to the racial differences in prostate cancer mortality.
BJU international 2005;96(9):1247-52.
2005: Michael F Sarosdy; Catherine M Tangen; Geoffrey R Weiss; Blake R Nestok; Mitchell C Benson; Paul F Schellhammer; Arthur I Sagalowsky; David P Wood Jr; E David Crawford
A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study.
Urologic oncology 2005;23(6):386-9.
2005: E David Crawford; Shandra S Wilson; Kathleen C Torkko; Daisaku Hirano; J Scott Stewart; Craig Brammell; R Storey Wilson; Nozomu Kawata; Holly Sullivan; M Scott Lucia; Priya N Werahera
Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy.
BJU international 2005;96(7):999-1004.
2005: Ulka Nitin Vaishampayan; James R Faulkner; Eric J Small; Bruce G Redman; Wayne L Keiser; Daniel P Petrylak; E David Crawford
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
Cancer 2005;104(8):1627-32.
2005: Bulent Akduman; Al Baha Barqawi; E David Crawford
Minimally invasive surgery in prostate cancer: current and future perspectives.
Cancer journal (Sudbury, Mass.) 2005;11(5):355-61.
2005: Ashutosh Tewari; Wolfgang Horninger; Ketan K Badani; Mazen Hasan; Steven Coon; E David Crawford; Eduard J Gamito; John T Wei; David Taub; James E Montie; Chris Porter; George Divine; Georg Bartsch; Mani Menon
Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
BJU international 2005;96(1):29-33.
2005: Peter J Van Veldhuizen; James R Faulkner; Primo Lara; Paul H Gumerlock; J Wendall Goodwin; Shaker R Dakhil; Howard M Gross; Robert C Flanigan; E David Crawford
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Cancer chemotherapy and pharmacology 2005;56(1):39-45.
2005: E David Crawford
Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile.
BJU international 2005;95 Suppl 4():1-5.
2005: Christopher R Porter; Eduard J Gamito; E David Crawford; Georg Bartsch; Joseph Charles Presti; Ashutosh Tewari; Colin O'Donnell
Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting.
Urology 2005;65(5):937-41.
2005: Ravi J Kumar; Albaha Barqawi; E David Crawford
Preventing and treating the complications of hormone therapy.
Current urology reports 2005;6(3):217-23.
2005: Edith D Canby-Hagino; Gregory Swanson; E David Crawford; Joseph W Basler; Javier Hernandez; Ian M Thompson
Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?
Current urology reports 2005;6(3):183-9.
2005: E David Crawford
PSA testing: what is the use?
Lancet 2005;365(9469):1447-9.
2005: Al Baha Barqawi; Brian K Golden; Colin O'Donnell; Michael K Brawer; E David Crawford
Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program.
Urology 2005;65(4):708-12.
2005: Paul D Maroni; E David Crawford
Surgical management of prostate cancer: optimizing patient selections and clinical outcome.
Surgical oncology clinics of North America 2005;14(2):301-19.
2005: Gerald L Andriole; David L Levin; E David Crawford; Edward P Gelmann; Paul F Pinsky; David Chia; Barnett S Kramer; Douglas Reding; Timothy R Church; Robert L Grubb; Grant Izmirlian; Lawrence R Ragard; Jonathan D Clapp; Philip C Prorok; John K Gohagan
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Journal of the National Cancer Institute 2005;97(6):433-8.
2005: Albaha Barqawi; E David Crawford
Focal therapy in prostate cancer: future trends.
BJU international 2005;95(3):273-4.
2005: Shandra S Wilson; E David Crawford
Genitourinary malignancies.
Cancer chemotherapy and biological response modifiers 2005;22():485-513.
2004: Tomasz M Beer; Catherine M Tangen; Lisa B Bland; Ian M Thompson; E David Crawford
Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894.
The Journal of urology 2004;172(6 Pt 1):2213-7.
2004: Daniel P Petrylak; Catherine M Tangen; Maha Hussain; Primo Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol M Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
The New England journal of medicine 2004;351(15):1513-20.
2004: Ali Ziada; Albaha Barqawi; L Michael Glode; Marileila Varella-Garcia; Frances Crighton; Susan Majeski; Mark Rosenblum; Madeleine Kane; Lin Chen; E David Crawford
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.
The Prostate 2004;60(4):332-7.
2004: E David Crawford; Albaha Barqawi
Intermediate- to high-risk prostate cancer patient treated with radiation therapy.
Oncology (Williston Park, N.Y.) 2004;18(9):1105-10.
2004: Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph W deVere White; Michael F Sarosdy; E David Crawford
Surgical factors influence bladder cancer outcomes: a cooperative group report.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(14):2781-9.
2004: Priya N Werahera; Gary J Miller; Kathleen C Torkko; E David Crawford; J Scott Stewart; Edward P DeAntoni; Heidi L Miller; M Scott Lucia
Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models.
Human pathology 2004;35(7):798-807.
2004: Shandra S Wilson; E David Crawford
Screening for prostate cancer.
Clinical prostate cancer 2004;3(1):21-5.
2004: Harry W Herr; James R Faulkner; H Barton Grossman; E David Crawford
Pathologic evaluation of radical cystectomy specimens: a cooperative group report.
Cancer 2004;100(11):2470-5.
2004: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
The New England journal of medicine 2004;350(22):2239-46.
2004: Shandra S Wilson; E David Crawford
Screening for prostate cancer: current recommendations.
The Urologic clinics of North America 2004;31(2):219-26.
2004: Eduard J Gamito; E David Crawford
Artificial neural networks for predictive modeling in prostate cancer.
Current oncology reports 2004;6(3):216-21.
2004: Ashutosh Tewari; Christine Cole Johnson; George Divine; E David Crawford; Eduard J Gamito; Raymond Demers; Mani Menon
Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.
The Journal of urology 2004;171(4):1513-9.
2004: Lin Qi; Terry M Nett; Matthew C Allen; Xiaoming Sha; Gail S Harrison; Barbara A Frederick; E David Crawford; L Michael Glode
Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor.
Cancer research 2004;64(6):2090-5.
2004: Ashutosh Tewari; Eduard J Gamito; E David Crawford; Mani Menon
Biochemical recurrence and survival prediction models for the management of clinically localized prostate cancer.
Clinical prostate cancer 2004;2(4):220-7.
2004: Albaha Barqawi; Eduard J Gamito; Colin O'Donnell; E David Crawford
Herbal and vitamin supplement use in a prostate cancer screening population.
Urology 2004;63(2):288-92.
2004: Albaha Barqawi; Ian M Thompson; E David Crawford
Prostate cancer chemoprevention: an overview of United States trials.
The Journal of urology 2004;171(2 Pt 2):S5-8; discussion S9.
2004: Ian M Thompson; Demetrius Albanes; Joseph W Basler; E David Crawford; Louis Denis; Bob Djavan; Neil Fleshner; Teresa Johnson-Pais; Eric A Klein; Alan R Kristal; M Scott Lucia; Howard L Parnes; Gary Piazza; Elizabeth A Platz; Bradley Pollock; Douglas K Price; Juergen K Reichardt; Catherine M Tangen; Anthony W Tolcher; Mary Carole McMann
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement.
The Journal of urology 2004;171(2 Pt 2):S3-4.
2004: Marileila Varella-Garcia; Bulent Akduman; Patrapim Sunpaweravong; Michael V Di Maria; E David Crawford
The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
Urologic oncology 2004;22(1):16-9.
2003: E David Crawford
Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks.
Urology 2003;62(6 Suppl 1):13-9.
2003: E David Crawford
Epidemiology of prostate cancer.
Urology 2003;62(6 Suppl 1):3-12.
2003: E David Crawford
Prostate cancer. Introduction.
Urology 2003;62(6 Suppl 1):1-2.
2003: John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias C Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin Slawin; Joseph A Smith
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
The New England journal of medicine 2003;349(25):2387-98.
2003: Al Baha Barqawi; Judd W Moul; Ali Ziada; Liann Handel; E David Crawford
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
Urology 2003;62(5):872-6.
2003: Al Baha Barqawi; Bulent Akduman; Z Abouelfadel; M Robischon; E David Crawford
The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer.
BJU international 2003;92(7):695-8.
2003: L Michael Glode; Albaha Barqawi; Frances Crighton; E David Crawford; Robert S Kerbel
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
Cancer 2003;98(8):1643-8.
2003: Christopher R Porter; E David Crawford
Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer.
Oncology (Williston Park, N.Y.) 2003;17(10):1395-9; discussion 1399, 1403-6.
2003: Nozomu Kawata; Gary J Miller; E David Crawford; Kathleen C Torkko; J Scott Stewart; M Scott Lucia; Heidi L Miller; Daisaku Hirano; Priya N Werahera
Laterally directed biopsies detect more clinically threatening prostate cancer: computer simulated results.
The Prostate 2003;57(2):118-28.
2003: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood Jr; Derek Raghavan; E David Crawford
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
The New England journal of medicine 2003;349(9):859-66.
2003: Siam Oottamasathien; E David Crawford
Recent advances in hormonal therapy for advanced prostate cancer.
Oncology (Williston Park, N.Y.) 2003;17(8):1047-52; discussion 1054-8.
2003: Catherine M Tangen; James R Faulkner; E David Crawford; Ian M Thompson; Daisaku Hirano; Mario A Eisenberger; Maha Hussain
Ten-year survival in patients with metastatic prostate cancer.
Clinical prostate cancer 2003;2(1):41-5.
2003: E David Crawford
My total prostate-specific antigen (PSA) level is 0.2 nanograms per milliliter, which I'm told is normal. But my free-to-total PSA ratio is 8 percent, which I've read indicates a high risk of prostate cancer. What do these seemingly contradictory PSA results mean?
Health news (Waltham, Mass.) 2003;9(6):12.
2003: Bulent Akduman; E David Crawford
The management of high risk prostate cancer.
The Journal of urology 2003;169(6):1993-8.
2003: E David Crawford
A 42-year-old woman with breast cancer.
Oncology (Williston Park, N.Y.) 2003;17(5):614; discussion 615-20.
2003: E David Crawford; David P Wood Jr; Daniel P Petrylak; Jennifer Scott; Charles A Coltman; Derek Raghavan
Southwest Oncology Group studies in bladder cancer.
Cancer 2003;97(8 Suppl):2099-108.
2003: Oliver M Bautista; John W Kusek; Leroy M Nyberg; John D McConnell; Raymond P Bain; Gary Miller; E David Crawford; Steven A Kaplan; Stephen A Sihelnik; Michael K Brawer; Hebert Lepor
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial.
Controlled clinical trials 2003;24(2):224-43.
2003: Siam Oottamasathien; E David Crawford
Should routine screening for prostate-specific antigen be recommended?
Archives of internal medicine 2003;163(6):661-2; discussion 666.
2003: E David Crawford
Early versus late hormonal therapy: debating the issues.
Urology 2003;61(2 Suppl 1):8-13.
2003: Tracy R Glass; Catherine M Tangen; E David Crawford; Ian M Thompson
Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning.
The Journal of urology 2003;169(1):164-9.
2002: Christopher R Porter; Colin O'Donnell; E David Crawford; Eduard J Gamito; Bridgitta Sentizimary; Angelo De Rosalia; Ashutosh Tewari
Predicting the outcome of prostate biopsy in a racially diverse population: a prospective study.
Urology 2002;60(5):831-5.
2002: Isaac J Powell; Catherine M Tangen; Gary J Miller; Bruce A Lowe; Gabriel P Haas; Peter R Carroll; Michael B Osswald; Ralph W deVere White; Ian M Thompson; E David Crawford
Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.
The Journal of urology 2002;168(5):2016-9.
2002: Zinelabidine Abouelfadel; Gary J Miller; L Michael Glode; Bulent Akduman; Robert E Donohue; Ann Nedrow; E David Crawford
High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade.
Clinical prostate cancer 2002;1(2):115-7.
2002: Catherine E Klein; Catherine M Tangen; Thomas J Braun; Maha Hussain; David M Peereboom; Craig Nichols; Saul E Rivkin; Shaker R Dakhil; E David Crawford
SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study.
The Prostate 2002;52(4):264-8.
2002: Ian M Thompson; Catherine M Tangen; Joseph W Basler; E David Crawford
Impact of previous local treatment for prostate cancer on subsequent metastatic disease.
The Journal of urology 2002;168(3):1008-12.
2002: E David Crawford
A 72-year-old man with prostate cancer.
Oncology (Williston Park, N.Y.) 2002;16(8):1014-6, 1119-21.
2001: Bulent Akduman; E David Crawford
Terazosin, doxazosin, and prazosin: current clinical experience.
Urology 2001;58(6 Suppl 1):49-54.
2001: Edward P Gelmann; David Chia; Paul F Pinsky; Gerald L Andriole; E David Crawford; Douglas Reding; Richard Hayes; Barnett S Kramer; D L Woodrum; John K Gohagan; David L Levin
Relationship of demographic and clinical factors to free and total prostate-specific antigen.
Urology 2001;58(4):561-6.
2001: Omer Kucuk; E Fisher; Carol M Moinpour; D Coleman; Maha Hussain; A O Sartor; Gurkamal S Chatta; Bruce A Lowe; Mario A Eisenberger; E David Crawford
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235).
Urology 2001;58(1):53-8.
2001: Ali Ziada; T C Lisle; P B Snow; R F Levine; G Miller; E David Crawford
Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network.
Cancer 2001;91(8 Suppl):1653-60.
2001: JT Batuello; Eduard J Gamito; E David Crawford; Misop Han; Alan W Partin; D G McLeod; C ODonnell
Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer.
Urology 2001;57(3):481-5.
2001: Kenneth Pienta; E I Fisher; Mario A Eisenberger; G M Mills; J Wendall Goodwin; Jeffrey A Jones; Shaker R Dakhil; E David Crawford; Maha Hussain
A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).
The Prostate 2001;46(4):257-61.
2001: AT Porter; Edgar Ben-Josef; E David Crawford; S Garde; I Huhtaniemi; J Edson Pontes
Advancing perspectives on prostate cancer: multihormonal influences in pathogenesis.
Molecular urology 2001;5(4):181-8.
2001: Ashutosh Tewari; M Issa; R El-Galley; Hans Stricker; James O Peabody; J Pow-Sang; A Shukla; Z Wajsman; M Rubin; John T Wei; James E Montie; Raymond Demers; Christine Cole Johnson; Lois Lamerato; George Divine; E David Crawford; Eduard J Gamito; R Farah; P Narayan; G Carlson; Mani Menon
Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study.
Molecular urology 2001;5(4):163-9.
2001: Chris Porter; Colin O'Donnell; E David Crawford; Eduard J Gamito; A Errejon; E Genega; T Sotelo; Ashutosh Tewari
Artificial neural network model to predict biochemical failure after radical prostatectomy.
Molecular urology 2001;5(4):159-62.
2001: A Errejon; E David Crawford; J Dayhoff; Colin O'Donnell; Ashutosh Tewari; J Finkelstein; Eduard J Gamito
Use of artificial neural networks in prostate cancer.
Molecular urology 2001;5(4):153-8.
2001: Ashutosh Tewari; Chris Porter; James O Peabody; E David Crawford; Raymond Demers; Christine Cole Johnson; John T Wei; George Divine; Colin O'Donnell; Eduard J Gamito; Mani Menon
Predictive modeling techniques in prostate cancer.
Molecular urology 2001;5(4):147-52.
2001: Maha Hussain; T R Glass; Jeffrey D Forman; Wael A Sakr; David C Smith; M al-Sarraf; J Jones; Stanley P Balcerzak; E David Crawford; H B Grossman
Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.
The Journal of urology 2001;165(1):56-60; discussion 60-1.
2000: Philip C Prorok; Gerald L Andriole; Robert S Bresalier; Saundra S Buys; David Chia; E David Crawford; Ronald Fogel; Edward P Gelmann; F Gilbert; Marsha Hasson; Richard Hayes; Christine Cole Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; Douglas Reding; W Rutt; Joel L Weissfeld; L Yokochi; John K Gohagan
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Controlled clinical trials 2000;21(6 Suppl):273S-309S.
2000: C I Suh; T Shanafelt; D J May; Kenneth R Shroyer; Joanna B Bobak; E David Crawford; Gary J Miller; Neil E Markham; L Michael Glode
Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer.
Molecular and cellular probes 2000;14(4):211-7.
2000: Eduard J Gamito; N N Stone; JT Batuello; E David Crawford
Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy.
Techniques in urology 2000;6(2):60-3.
2000: E David Crawford; JT Batuello; P Snow; Eduard J Gamito; D G McLeod; Alan W Partin; N Stone; James E Montie; Richard Stock; J Lynch; J Brandt
The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma.
Cancer 2000;88(9):2105-9.
2000: D L Lamm; Brent Blumenstein; JD Crissman; James E Montie; J E Gottesman; Bruce A Lowe; Michael F Sarosdy; R D Bohl; H Barton Grossman; T M Beck; J T Leimert; E David Crawford
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
The Journal of urology 2000;163(4):1124-9.
2000: Stephen K Williamson; D Lew; G J Miller; Stanley P Balcerzak; Laurence H Baker; E David Crawford
Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Cancer 2000;88(5):1159-65.
2000: Maha Hussain; E I Fisher; Daniel P Petrylak; J O'Connor; David P Wood Jr; Eric J Small; Mario A Eisenberger; E David Crawford
Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):1043-9.
1999: E David Crawford
Summary: the role of the urologist in chemotherapy of hormone refractory prostate cancer.
Urology 1999;54(6A Suppl):51-2.
1999: E David Crawford; Mark Rosenblum; Ali Ziada; P H Lange
Hormone refractory prostate cancer.
Urology 1999;54(6A Suppl):1-7.
1999: Ali Ziada; F Grover; E David Crawford
The use of trans-oesophageal echocardiography in the management of intra-atrial thrombus in a patient with renal cell carcinoma.
BJU international 1999;84(6):737-8.
1999: Gabriel P Haas; Brent Blumenstein; R G Gagliano; C A Russell; S E Rivkin; D J Culkin; M Wolf; E David Crawford
Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study.
The Journal of urology 1999;161(6):1823-5.
1999: Michael F Sarosdy; Paul F Schellhammer; Mark S Soloway; Nicholas J Vogelzang; E David Crawford; J Presti; Gerald Chodak; P Mitchell; L Porter
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.
BJU international 1999;83(7):801-6.
1999: S Goktas; E David Crawford
Optimal hormonal therapy for advanced prostatic carcinoma.
Seminars in oncology 1999;26(2):162-73.
1999: Ali Ziada; Mark Rosenblum; E David Crawford
Benign prostatic hyperplasia: an overview.
Urology 1999;53(3 Suppl 3a):1-6.
1999: E David Crawford; S Leewansangtong; S Goktas; K Holthaus; M Baier
Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values.
The Prostate 1999;38(4):296-302.
1999: E David Crawford
The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials.
European urology 1999;35(5-6):511-4.
1998: Ali Ziada; E David Crawford
Securing urethral catheters in patients undergoing urethrovesical anastomosis.
Techniques in urology 1998;4(4):210-1.
1998: Carol M Moinpour; M J Savage; A Troxel; Laura C Lovato; Mario A Eisenberger; R W Veith; B Higgins; R Skeel; M Yee; B A Blumenstein; E David Crawford; Frank L Meyskens
Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
Journal of the National Cancer Institute 1998;90(20):1537-44.
1998: Mario A Eisenberger; Brent Blumenstein; E David Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; Ian M Thompson; A J Bueschen; Bruce A Lowe
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
The New England journal of medicine 1998;339(15):1036-42.
1998: S Leewansangtong; S Goktas; R Lepoff; K Holthaus; E David Crawford
Comparability of serum prostate-specific antigen measurement between the hybritech Tandem-R and Abbott AxSYM assays.
Urology 1998;52(3):467-9.
1998: Daisaku Hirano; Priya N Werahera; E David Crawford; M Scott Lucia; Edward P DeAntoni; Gary J Miller
Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy.
The Journal of urology 1998;159(4):1265-9.
1998: E David Crawford; Daisaku Hirano; Priya N Werahera; M Scott Lucia; Edward P DeAntoni; Firouz Daneshgari; P N Brawn; V O Speights; J Scott Stewart; Gary J Miller
Computer modeling of prostate biopsy: tumor size and location--not clinical significance--determine cancer detection.
The Journal of urology 1998;159(4):1260-4.
1998: J Stenner; K Holthaus; S H Mackenzie; E David Crawford
The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population.
Urology 1998;51(3):455-9.
1997: E David Crawford
Prostate Cancer Awareness Week: September 22 to 28, 1997.
CA: a cancer journal for clinicians 1997;47(5):288-96.
1997: E David Crawford; Charles L Bennett; N N Stone; Sara J Knight; Edward P DeAntoni; L Sharp; M B Garnick; HA Porterfield
Comparison of perspectives on prostate cancer: analyses of survey data.
Urology 1997;50(3):366-72.
1997: E David Crawford; Edward P DeAntoni; Maha Hussain; Ian M Thompson; Charles A Coltman
Prostate cancer clinical trials of the Southwest Oncology Group.
Oncology (Williston Park, N.Y.) 1997;11(8):1154-63; discussion 1163-70.
1997: Julie A Kish; M K Wolf; P F Schellhammer; Maha Hussain; A B Einstein; E David Crawford
Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.
American journal of clinical oncology 1997;20(4):327-30.
1997: M Nishiya; E David Crawford
Perineal cystoprostatectomy and ureterosigmoidostomy for invasive bladder cancer.
The Journal of urology 1997;157(6):2227-9.
1997: S Waxman; A K Stevens; R A Walsh; S H Mackenzie; E David Crawford
Management of asymptomatic rising PSA after prostatectomy or radiation therapy.
Oncology (Williston Park, N.Y.) 1997;11(4):457-60, 465; discussion 465-6, 469.
1997: D G McLeod; E David Crawford; E P DeAntoni
Combined androgen blockade: the gold standard for metastatic prostate cancer.
European urology 1997;32 Suppl 3():70-7.
1997: E David Crawford
Prostate cancer: to screen or not to screen?
Oncology (Williston Park, N.Y.) 1997;11(1):50, 55-6, 59.
1996: Edward P DeAntoni; E David Crawford; J E Oesterling; C A Ross; E R Berger; David G McLeod; F Staggers; N N Stone
Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study.
Urology 1996;48(2):234-9.
1996: E David Crawford; Edward P DeAntoni; R Etzioni; V C Schaefer; R M Olson; C A Ross
Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council.
Urology 1996;47(6):863-9.
1996: E David Crawford; Edward P DeAntoni; C A Ross
The role of prostate-specific antigen in the chemoprevention of prostate cancer.
Journal of cellular biochemistry. Supplement 1996;25():149-55.
1996: E David Crawford
Combined androgen blockade.
European urology 1996;29 Suppl 2():54-61.
1995: R L Cox; E David Crawford
Estrogens in the treatment of prostate cancer.
The Journal of urology 1995;154(6):1991-8.
1995: E DeAntoni; E David Crawford
[Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
Der Urologe. Ausg. A 1995;34(5):382-8.
1995: S A Grampsas; Gary J Miller; E David Crawford
Salvage radical prostatectomy after failed transperineal cryotherapy: histologic findings from prostate whole-mount specimens correlated with intraoperative transrectal ultrasound images.
Urology 1995;45(6):936-41.
1995: R L Cox; E David Crawford
Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate.
Urology 1995;45(6):932-5.
1995: F Daneshgari; G D Taylor; Gary J Miller; E David Crawford
Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies.
Urology 1995;45(4):604-9.
1995: E David Crawford; E P DeAntoni
Current status of combined androgen blockade: optimal therapy for advanced prostate cancer.
The Journal of clinical endocrinology and metabolism 1995;80(4):1062-6.
1995: S W Waxman; E David Crawford
Advanced prostate cancer.
Surgical technology international 1995;IV():266-70.
1995: E David Crawford; Maha Hussain; Edward P DeAntoni; Ian M Thompson; Mario A Eisenberger; B Blumenstein; C A Coltman
Southwest Oncology Group strategies in prostatic carcinoma.
Seminars in surgical oncology 1995;11(1):60-4.
1994: M Nishiya; G J Miller; D H Lookner; E David Crawford
Prostate specific antigen density in patients with histologically proven prostate carcinoma.
Cancer 1994;74(11):3002-9.
1994: F J Mayer; E David Crawford
The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
The Urologic clinics of North America 1994;21(4):707-15.
1994: E P DeAntoni; E David Crawford
Pretreatment of metastatic disease. Prostate cancer in the older male.
Cancer 1994;74(7 Suppl):2182-7.
1994: Mario A Eisenberger; E David Crawford; M Wolf; B Blumenstein; David G McLeod; R Benson; F A Dorr; M Benson; J T Spaulding
Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.
Seminars in oncology 1994;21(5):613-9.
1994: E David Crawford; J M Kozlowski; F M Debruyne; W R Fair; C J Logothetis; C Balmer; R G Robinson; AT Porter; D Kirk
The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer.
Urology 1994;44(4):481-5.
1993: David G McLeod; R C Benson; Mario A Eisenberger; E David Crawford; B A Blumenstein; D Spicer; J T Spaulding
The use of flutamide in hormone-refractory metastatic prostate cancer.
Cancer 1993;72(12 Suppl):3870-3.
1993: E A Andros; F Danesghari; E David Crawford
Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate.
Clinical and investigative medicine. Médecine clinique et experimentale 1993;16(6):510-5.
1993: Edward P DeAntoni; E David Crawford; N N Stone; D S Blum; E R Berger; Mario A Eisenberger; Steven Gambert; F Staggers
Prostate Cancer Awareness Week, 1992: a summary of key findings.
Clinical and investigative medicine. Médecine clinique et experimentale 1993;16(6):448-57.
1993: E David Crawford; Edward P DeAntoni
PSA as a screening test for prostate cancer.
The Urologic clinics of North America 1993;20(4):637-46.
1993: B Blumenstein; E David Crawford; J H Saiers; R L Stephens; S E Rivkin; C A Coltman
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
The Journal of urology 1993;150(2 Pt 1):411-3.
1993: F Daneshgari; E David Crawford
Benign prostatic disease. A growing challenge in the 1990s.
Postgraduate medicine 1993;93(7):84-92.
1993: F Daneshgari; E David Crawford
Endocrine therapy of advanced carcinoma of the prostate.
Cancer 1993;71(3 Suppl):1089-97.
1992: E David Crawford; F Daneshgari; S A Majeski
Etoposide in the treatment of hormone-refractory advanced carcinoma of the prostate.
Seminars in oncology 1992;19(6 Suppl 14):53-7.
1992: P A Seligman; P L Moran; R B Schleicher; E David Crawford
Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo.
American journal of hematology 1992;41(4):232-40.
1992: David G McLeod; E David Crawford; B A Blumenstein; Mario A Eisenberger; F A Dorr
Controversies in the treatment of metastatic prostate cancer.
Cancer 1992;70(1 Suppl):324-8.
1992: E David Crawford; P Goodman; W L Nabors; R L Stephens; K Khan; L M Pass; A Y Smith; D W Christie
Treatment of stages B3 and C seminoma with chemotherapy followed by irradiation therapy. Southwest Oncology Group Study.
Urology 1992;39(5):457-60.
1992: E David Crawford; F Daneshgari
Management of regional lymphatic drainage in carcinoma of the penis.
The Urologic clinics of North America 1992;19(2):305-17.
1992: E David Crawford; N S Berger; M A Davis; R E Donohue
Prevention of urinary tract infection and bacteremia following transurethral surgery: oral lomefloxacin compared to parenteral cefotaxime.
The Journal of urology 1992;147(4):1053-5.
1992: E David Crawford; W R Fair; G J Kelloff; M M Lieber; Gary J Miller; P T Scardíno; Edward P DeAntoni
Chemoprevention of prostate cancer: guidelines for possible intervention strategies.
Journal of cellular biochemistry. Supplement 1992;16H():140-5.
1991: P A Seligman; E David Crawford
Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate.
Journal of the National Cancer Institute 1991;83(21):1582-4.
1991: E David Crawford
Benign and malignant prostatic diseases.
American family physician 1991;44(5 Suppl):65S-70S.
1991: R C Benson; E David Crawford; Mario A Eisenberger; David G McLeod; J T Spaulding; F A Dorr
National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo.
Seminars in oncology 1991;18(5 Suppl 6):9-12.
1991: E David Crawford; J H Saiers; Laurence H Baker; J H Costanzi; R M Bukowski
Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study.
Urology 1991;38(4):355-7.
1991: E David Crawford; W L Nabors
Total androgen ablation: American experience.
The Urologic clinics of North America 1991;18(1):55-63.
1991: A C Philpott; E David Crawford; G J Miller
A new method for assaying antimicrobials in the prostate.
Infection 1991;19 Suppl 3():S150-3.
1990: E David Crawford; J A Allen
Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.
The Journal of steroid biochemistry and molecular biology 1990;37(6):961-3.
1990: E David Crawford
Hormonal therapy of prostatic carcinoma. Defining the challenge.
Cancer 1990;66(5 Suppl):1035-8.
1990: E David Crawford; B A Blumenstein; P J Goodman; M A Davis; Mario A Eisenberger; David G McLeod; J T Spaulding; R Benson; F A Dorr
Leuprolide with and without flutamide in advanced prostate cancer.
Cancer 1990;66(5 Suppl):1039-44.
1990: E David Crawford; P Goodman; B Blumenstein
Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
Seminars in urology 1990;8(3):154-8.
1990: E David Crawford; R B Natale; H Burton
Southwest Oncology Group Study 8710: trial of cystectomy alone versus neo-adjuvant M-VAC and cystectomy in patients with locally advanced bladder cancer (Intergroup Trial 0080).
Progress in clinical and biological research 1990;353():111-3.
1990: E David Crawford
Combination studies with leuprolide.
European urology 1990;18 Suppl 3():30-3.
1990: W Nabors; E David Crawford
Luteinizing hormone releasing hormone agonists: the US experience.
The Journal of international medical research 1990;18 Suppl 1():31-4.
1989: E David Crawford
Combined androgen blockade.
Urology 1989;34(4 Suppl):22-6; discussion 46-56.
1989: E David Crawford; Mario A Eisenberger; David G McLeod; J T Spaulding; R Benson; F A Dorr; B A Blumenstein; M A Davis; P J Goodman
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
The New England journal of medicine 1989;321(7):419-24.
1989: E David Crawford
The role of ultrasound in prostatic imaging. Introduction and overview.
Urology 1989;33(6 Suppl):2-6.
1988: J E Foote; E David Crawford
Total androgen suppression: are there any advantages? The use of combined therapy in the treatment of advanced prostate adenocarcinoma.
Seminars in urology 1988;6(4):291-302.
1987: E David Crawford; S Das; J A Smith
Preoperative radiation therapy in the treatment of bladder cancer.
The Urologic clinics of North America 1987;14(4):781-7.